About

Who we Are

Airway Innovations^™ develops next-generation airway management devices.

Our focus is on anesthesia devices that enhance patient care and streamline the workflow of healthcare providers.

AERIS_Beauty_shot_tip_pointing_to_left_(1).png

Our first product, the AERIS Airway^™, transforms oral pharyngeal (OPA) and nasopharyngeal airways (NPAs) into state-of-the-art O₂ delivery and ETCO₂ monitoring devices.

With the AERIS^™ in use during I.V. sedation, FIO₂ approaches 80% at O₂ flow rates as low as 2-4 L/min while a real-time, precise ETCO₂ waveform is produced.

We believe it is no longer acceptable that hypoxemia remains one of the leading causes of morbidity and mortality during anesthesia care.

That is why we developed the AERIS Airway^™.

Key Milestones

What led Airway Innovations^™ to develop the AERIS Airway^™...

2011

The American Society of Anesthesiologists (ASA) updates its guidelines, recommending capnography for all patients undergoing I.V. sedation to detect hypoventilation before desaturation occurs.

2014

The Joint Commission (TJC) begins emphasizing capnography use during I.V. sedation for patient safety.

2025

Airway Innovations^™ launches the Airway to meet ASA and TJC guidelines by preemptively detecting and preventing hypoxemia.

Our Vision

At Airway Innovations^™, we are committed to developing airway management devices that improve patient safety, streamline the workflow of anesthesia providers, and reduce the cost of healthcare.

Simple. Safer. Sedation.

Ready to Transform I.V. Sedation?

Contact us to bring AERIS^™ to your facility.